NRG-CC008: A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]

February 08 2022

The NRG-CC008/SOROCk trial builds on clinical and translational research that suggests most ovarian cancers begin in the distal fallopian tube. Preliminary data from the SU2C WISP trial has shown that leaving ovaries in place, but removing the tubes helps younger, high-risk (BRCA mutation) women retain hormonal function. However, the SU2C WISP trial was not designed to determine whether or not removing just the tubes – instead of both tubes and ovaries – prevents ovarian cancer. What is needed is a decisive clinical trial.

Along these lines, the SOROCk trial is an international clinical trial, designed to convert this preliminary data into clinical action. This study aims to define the role of tube versus ovary removal on cancer incidence. It is a non-randomized trial where BRCA1 carriers will self-select their preferred surgical intervention. This trial will determine if bilateral salpingectomy is non-inferior to bilateral salpingo-oophorectomy to reduce the risk of ovarian cancer. 

“This is a critically important study as we need a properly powered trial to address the impact of bilateral salpingectomy on ovarian cancer incidence,” comments Warner K. Huh, MD, of the UAB Department of Obstetrics/Gynecology and the O’Neal Comprehensive Cancer Center and Co-Principal Investigator of the NRG-CC008 trial.

As of this writing, 110 patients have been enrolled onto this trial.

View the NRG Oncology SOROCk Webpage

Stay current with science. Sign up for our newsletter.

Support NRG Oncology.
Help Our Cause.

We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More

Donate Today

NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.